Compare Merck & Co., Inc. (MRK) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while iShares 1 3 Year Treasury Bond ETF trades at $81.66. The key difference: Merck & Co., Inc. pays a 2.29% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SHY | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $83.18 |
52-Week Low | $77.60 | $81.59 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SHY is currently trading at $81.66, showing minimal daily movement with a slight decline of 0.04%. The technical picture appears bearish with moving averages signaling caution, though oscillators suggest some buying opportunity. Recent corporate actions include consistent dividend payments scheduled through mid-2026, providing income stability for shareholders amid market volatility.
The outlook for SHY reflects mixed signals with technical indicators showing bearish momentum but potential oversold conditions. Investment opportunities include dividend income stability, while risks center on broader bond market volatility and interest rate sensitivity. The stock faces headwinds from rising Treasury yields and inflation concerns that could pressure fixed-income investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
